OrbiMed’s Clearside Biomedical CLSD Stock Holding History

OrbiMed’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-20,000	Closed	-$2.38M	–	142
2017 Q1	$2.38M	Hold	20,000	–	–	0.03%	125
2016 Q4	$2.68M	Buy	+20,000	New	+$5.02M	0.03%	119

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

OrbiMed's CLSD Position: Q2 2017 in Review

OrbiMed sold out of Clearside Biomedical (CLSD) in Q2 2017, closing a stake of 20,000 shares — an estimated $2.38M sold.

OrbiMed first reported a position in CLSD in Q4 2016 and held it in 2 quarters. The position peaked at $2.68M in Q4 2016. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2017.

OrbiMed reported no remaining Clearside Biomedical position as of Q2 2017 after selling out during the quarter.
OrbiMed sold 20,000 Clearside Biomedical shares in Q2 2017, an estimated $2.38M.
OrbiMed first reported a position in Clearside Biomedical in Q4 2016 and held it in 2 quarters.
OrbiMed's Clearside Biomedical position peaked at $2.68M in Q4 2016.
53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2017.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.